, also known as Faslodex or Fulzos, is a drug used to treat certain types of breast disease. It is an endocrine therapy that is classified as a selective estrogen receptor degrader (SERD). It is frequently used to treat advanced or metastatic breast illness that is hormone receptor-positive, human epidermal growth factor receptor 2-negative, and has a distinct and powerful mode of action. It attaches itself to the receptors for the hormone estrogen on ill cells, preventing the growth-promoting actions of this hormone on breast cancerous cells. Unlike other endocrine therapies, such as selective estrogen receptor modulators (SERMs), such as tamoxifen, it blocks the receptors and causes them to degrade, effectively reducing the number of estrogen receptors available to bind.
It is commonly used to treat HR+/HER2- type advanced or metastatic breast disease, especially those who are resistant to or ineffective against aromatase inhibitors (such as anastrozole, letrozole) or other anti-estrogen drugs (such as tamoxifen). It has shown promising efficacy as a monotherapy for postmenopausal women who have received other endocrine therapies but have disease progression. It can also be combined with other targeted therapies, such as CDK4/6 or PI3K inhibitors. This combination therapy has significant advantages in delaying disease progression and prolonging progression-free survival. If you are interested in this product, please get in touch with Xi'an Songwu. Xi'an Songwu can supply phenibut nootropics for a long time.
They are both endocrine (hormone) therapies used to treat hormone receptor-positive (HR+) breast cancer, but they differ in their mechanisms of action, clinical uses, and side effect profiles.
1. Mechanism of Action
This compound is a selective estrogen receptor degrader (SERD). It binds to estrogen receptors (ERs) on diseased cells, preventing estrogen from binding and activating the receptors. In addition, it promotes the degradation of the estrogen receptors themselves, effectively reducing the number of receptors to which estrogen can bind. This dual mechanism blocks and reduces estrogen signaling in breast-diseased cells, decreasing diseased cell growth.
An aromatase inhibitor (AI) is letrozole. It blocks the aromatase enzyme, which in postmenopausal women changes androgens (hormones made by the adrenal glands) into estrogens. Letrozole lowers the amount of estrogen available to encourage the growth of HR+ breast-diseased cells by lowering estrogen levels in the body.
2. Indications and Uses
It is typically used in postmenopausal women with advanced or metastatic HR+ breast disease. It is generally utilized when other endocrine medications, including tamoxifen or aromatase inhibitors, are ineffective in treating the condition. It can be used as monotherapy or combined with other targeted therapies, such as CDK4/6 or PI3K inhibitors, to improve outcomes.
They are used as adjuvant therapy (post-surgery) to lower the incidence of recurrence of early-stage HR+ breast disease in postmenopausal women. It is also used for advanced or metastatic HR+ breast disease. It is often used with other drugs, such as CDK4/6 or mTOR inhibitors, to enhance efficacy.
3. Resistance and Sequential Therapy
They are often used as first-line therapy. Resistance can develop over time, and once progression occurs, treatment can be switched to fulvestrant or combined with other targeted therapies.
1. Clinical efficacy
Clinical studies have shown that it can prolong the progression-free survival (PFS) of patients with advanced HR+ breast lesions. Mainly, when used in combination with other targeted therapy drugs, it can significantly increase PFS, allowing patients to survive longer without the need to change treatment. In some studies, fulvestrant, especially at a higher dose of 500 mg, has shown the effect of improving overall survival (OS) in specific patient populations. Compared to a single endocrine treatment, the patient's survival was further extended by combination therapy with CDK4/6 inhibitors.
2. Overcoming endocrine therapy resistance
3. Impact on quality of life
It can help maintain or improve patients' quality of life by effectively controlling the progression of HR+ breast disease. Symptoms associated with disease progression (such as pain, fatigue, and loss of appetite) are generally less common in patients taking it than in patients progressing on other treatments.
1. Avoid grapefruit and grapefruit juice
While grapefruit does not significantly affect fulvestrant, many other drugs combined with it may interact with grapefruit. Grapefruit and its juice can inhibit certain enzymes in the liver (CYP3A4), which can affect the metabolism of these drugs, potentially leading to side effects or increased toxicity.
2. Limit alcohol intake
3. Avoid foods high in saturated and trans fats
4. Be cautious with herbal supplements and green tea
High-fiber foods: Constipation, which can occasionally result from cancer therapy, is one of the digestive side effects that whole grains, fruits, vegetables, and legumes might help alleviate.
Anti-inflammatory foods: Foods high in omega-3 fatty acids and antioxidants, such as berries, leafy greens, nuts, and fatty fish, can boost the immune system and help control inflammation.